Literature DB >> 16274776

Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links.

Gregory Y H Lip, George I Varughese.   

Abstract

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, which is also associated with a substantial risk of mortality and morbidity from stroke, thromboembolism, heart failure and hospitalisations. On a epidemiological basis, diabetes mellitus is commonly associated with AF. Nonetheless, AF is also associated with vascular disease and hypertension, which are themselves intimately linked to diabetes. Indeed, the precise pathophysiological and clinical relationships between AF and diabetes mellitus are not completely understood. What we do know is that both diabetes and AF are individually bad for our patients, and the presence of both requires aggressive management strategies.

Entities:  

Mesh:

Year:  2005        PMID: 16274776     DOI: 10.1016/j.ijcard.2005.03.003

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  18 in total

Review 1.  Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure.

Authors:  Yana Anfinogenova; Elena V Grakova; Maria Shvedova; Kristina V Kopieva; Alexander T Teplyakov; Sergey V Popov
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

Review 2.  Catheter ablation in atrial fibrillation: is there a mortality benefit in patients with diabetes and heart failure?

Authors:  M Matta; A Saglietto; P De Salvo; A Bissolino; A Ballatore; M Anselmino
Journal:  Herz       Date:  2019-05       Impact factor: 1.443

3.  HbA1c levels as predictors of ablation outcome in type 2 diabetes mellitus and paroxysmal atrial fibrillation.

Authors:  Z-H Lu; N Liu; R Bai; Y Yao; S-N Li; R-H Yu; C-H Sang; R-B Tang; D-Y Long; X Du; J-Z Dong; C-S Ma
Journal:  Herz       Date:  2014-10-23       Impact factor: 1.443

Review 4.  A review of factors associated with maintenance of sinus rhythm after elective electrical cardioversion for atrial fibrillation.

Authors:  Veronika Ecker; Charles Knoery; Gordon Rushworth; Ian Rudd; Astrid Ortner; David Begley; Stephen J Leslie
Journal:  Clin Cardiol       Date:  2018-06-07       Impact factor: 2.882

Review 5.  Role of diabetes in heart rhythm disorders.

Authors:  Buelent Koektuerk; Murat Aksoy; Marc Horlitz; Ilkay Bozdag-Turan; Ramazan Goekmen Turan
Journal:  World J Diabetes       Date:  2016-02-10

Review 6.  Clinical pharmacokinetics and pharmacodynamics of vildagliptin.

Authors:  Yan-Ling He
Journal:  Clin Pharmacokinet       Date:  2012-03-01       Impact factor: 6.447

7.  Diabetes mellitus, glycemic control, and risk of atrial fibrillation.

Authors:  Sascha Dublin; Nicole L Glazer; Nicholas L Smith; Bruce M Psaty; Thomas Lumley; Kerri L Wiggins; Richard L Page; Susan R Heckbert
Journal:  J Gen Intern Med       Date:  2010-04-20       Impact factor: 5.128

8.  Sitagliptin Modulates the Electrical and Mechanical Characteristics of Pulmonary Vein and Atrium.

Authors:  Chien-Jung Chang; Ten-Fang Yang; Tin-I Lee; Yao-Chang Chen; Yu-Hsun Kao; Shih-Ann Chen; Yi-Jen Chen
Journal:  Acta Cardiol Sin       Date:  2014-01       Impact factor: 2.672

9.  P-wave duration and dispersion in obese subjects.

Authors:  Feridun Kosar; Yüksel Aksoy; Fahri Ari; Lezzan Keskin; Ibrahim Sahin
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-01       Impact factor: 1.468

10.  Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation.

Authors:  Lynette Pretorius; Xiao-Jun Du; Elizabeth A Woodcock; Helen Kiriazis; Ruby C Y Lin; Silvana Marasco; Robert L Medcalf; Ziqiu Ming; Geoffrey A Head; Joon Win Tan; Nelly Cemerlang; Junichi Sadoshima; Tetsuo Shioi; Seigo Izumo; Elena V Lukoshkova; Anthony M Dart; Garry L Jennings; Julie R McMullen
Journal:  Am J Pathol       Date:  2009-08-13       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.